Skip to content
Buy This GLP
← Research
Evidence

Can a GLP-1 Replace Mealtime Insulin in Type 2 Diabetes?

Seven randomized trials examined reducing or stopping scheduled mealtime insulin while keeping basal insulin in the treatment plan.

Editorial profile: Neil SandersBuy This GLP Editorial Team4 min read
Difference versus continued insulin therapyHbA1c−0.08 percentage pointsBody weight−4.94 kgTotal daily insulin−33.32 units/day

Some adults with type 2 diabetes can reduce or stop scheduled mealtime insulin after starting a GLP-1 medicine under medical supervision. The trials tested this strategy while keeping basal insulin in the treatment plan. People with type 1 diabetes still need insulin [1] [3].

What’s approved and how treatment changes are made

The FDA label for Ozempic injection includes improving blood sugar in adults with type 2 diabetes. Our Wegovy and Ozempic comparison explains how the labeled uses differ. Ozempic’s label does not list insulin replacement as a distinct indication[4]. The ADA and EASD advise closer monitoring when a potent medicine is added to insulin, and some people still need mealtime insulin to reach glucose goals[5]. Ask your diabetes care team before stopping or changing insulin.

What changing mealtime insulin did in the trials

The trials used clinical protocols to withdraw, replace or substantially reduce scheduled mealtime insulin. The pooled difference in HbA1c change was −0.08 percentage points (95% confidence interval −0.28 to 0.12) with the GLP-1 strategy versus continued intensive insulin treatment. The analysis did not establish that the strategies were equivalent [1].

Compared with continuing the insulin regimen, the GLP-1 strategy was associated with −4.94 kg in body weight (95% confidence interval −7.37 to −2.51 kg) and −33.32 units per day in total insulin (−52.23 to −14.41). These are differences between groups[1].

In one of the trials, TRANSITION-T2D, 60 adults whose type 2 diabetes was already reasonably controlled were assigned to semaglutide plus basal insulin or to continue multiple daily insulin injections. At 26 weeks, 97.5% of the semaglutide group had stopped scheduled mealtime insulin. The trial was small and enrolled selected patients [2].

What the trials tell us about cost

Our guide to GLP-1 insurance coverage explains why out-of-pocket costs can vary by plan and indication. These trials do not establish what either treatment will cost a particular person.

Frequently asked

Can a GLP-1 replace insulin?
Some adults with type 2 diabetes may be able to reduce or stop scheduled mealtime insulin with clinical supervision. The pooled trials maintained basal insulin. People with type 1 diabetes still need insulin.
What happened to blood sugar in the trials?
The pooled difference in HbA1c change was −0.08 percentage points, with a 95% confidence interval of −0.28 to 0.12. The analysis did not find a statistically significant difference over the periods studied.
Did the strategy reduce the risk of low blood sugar?
The pooled risk ratio for at least one low blood sugar event was 0.76, with a 95% confidence interval of 0.66 to 0.87. The review authors cautioned that a reduction remains uncertain.

Sources

  1. [1] Yang H, et al. (2026). GLP-1 Receptor Agonist-Based Prandial Insulin De-Intensification in Outpatients With Type 2 Diabetes Receiving Basal-Bolus Insulin Therapy or Multiple Daily Injections: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Diabetes, Obesity and Metabolism. PMID 42736042
  2. [2] Rodriguez P, Breslaw N, Xiao H, et al. (2025). De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes (TRANSITION-T2D) Diabetes, Obesity and Metabolism. PMID 39532398
  3. [3] American Diabetes Association Professional Practice Committee (2026). Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 Diabetes Care. Source
  4. [4] Novo Nordisk (2026). Ozempic injection prescribing information, sections 1 and 5.5 Drugs@FDA. Source
  5. [5] American Diabetes Association and European Association for the Study of Diabetes (2026). Management of type 2 diabetes, 2026: A consensus report Diabetologia. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence